| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0,0 € | — | — | — | — | — | — | — | ||||||||||||
| Gross margin | 136,6 k € | -77.5% | 606,8 k € | +4.2% | 582,3 k € | -15.4% | 688,2 k € | +30.0% | 529,5 k € | -19.3% | 655,9 k € | +518.5% | 106,0 k € | +582.1% | 15,5 k € | -93.9% | 256,3 k € | +246.0% | 74,1 k € | +202.0% | -72,6 k € | +51.0% | -148,1 k € | |
| EBITDA | -280,7 k € | -345.3% | 114,4 k € | -22.9% | 148,3 k € | -57.3% | 347,6 k € | +22.5% | 283,8 k € | -43.3% | 500,6 k € | +1063.4% | -52,0 k € | +62.3% | -137,7 k € | -242.2% | 96,8 k € | +188.1% | -109,9 k € | +16.9% | -132,2 k € | +21.6% | -168,5 k € | |
| Operating profit | -590,1 k € | -148.0% | -237,9 k € | -18.3% | -201,2 k € | -341.9% | 83,2 k € | +24.2% | 67,0 k € | -77.0% | 291,6 k € | +198.4% | -296,5 k € | +13.1% | -341,2 k € | -1057.8% | -29,5 k € | +81.7% | -161,2 k € | -13.1% | -142,6 k € | +32.4% | -211,0 k € | |
| Profit/loss | -620,7 k € | -136.9% | -262,0 k € | -17.9% | -222,3 k € | -560.7% | 48,3 k € | -17.6% | 58,5 k € | -79.2% | 281,5 k € | +192.4% | -304,6 k € | +13.5% | -352,2 k € | -888.8% | -35,6 k € | +78.1% | -162,8 k € | -21.9% | -133,6 k € | +30.5% | -192,3 k € | |
| Equity | 2,6 M € | +3.1% | 2,5 M € | -9.6% | 2,7 M € | +10.1% | 2,5 M € | +64.0% | 1,5 M € | +4.0% | 1,5 M € | +153.0% | 576,3 k € | -34.3% | 877,4 k € | +43.7% | 610,6 k € | +76.6% | 345,8 k € | +32.9% | 260,1 k € | +12.3% | 231,7 k € | |
| Total assets | 4,1 M € | +13.1% | 3,6 M € | -5.1% | 3,8 M € | +8.8% | 3,5 M € | +32.8% | 2,7 M € | +6.6% | 2,5 M € | +38.3% | 1,8 M € | -7.1% | 1,9 M € | +36.0% | 1,4 M € | +38.0% | 1,0 M € | +180.3% | 368,3 k € | +54.1% | 238,9 k € | |
| Cash | 371,7 k € | +45.5% | 255,4 k € | -31.2% | 371,3 k € | -18.2% | 454,1 k € | +8.4% | 418,9 k € | -44.0% | 748,3 k € | +655.0% | 99,1 k € | -75.5% | 404,7 k € | +12.7% | 359,2 k € | +82.4% | 196,9 k € | +115.6% | 91,3 k € | +261.2% | 25,3 k € | |
| Debts | 1,6 M € | +34.3% | 1,2 M € | +6.2% | 1,1 M € | +5.9% | 1,0 M € | -8.9% | 1,1 M € | +10.2% | 1,0 M € | -15.6% | 1,2 M € | +15.3% | 1,1 M € | +30.3% | 813,4 k € | +18.5% | 686,4 k € | +534.7% | 108,1 k € | +1401.1% | 7,2 k € | |
| Staff | — | 5,7 | 5,6 | — | — | — | — | — | — | — | 1,4 | 0,7 | ||||||||||||
Public limited company · Marche-en-Famenne · incorporated on 06/11/2013
Public limited company loss-making in the latest fiscal year. Cash position rising (+45.5%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
RevaTis is a Public limited company incorporated in 2013. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Marche-en-Famenne.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette